PSMA inhibitor-based radiopharmaceuticals for diagnosis and therapy of prostate cancer
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
Mainz, Johannes Gutenberg-Universität Mainz, Dissertation, 2022
- Schlagwort
-
Therapeutics
Prostate--Cancer
Radiopharmaceuticals
Diagnosis
- Ereignis
-
Veröffentlichung
- (wo)
-
Mainz
- (wer)
-
Universitätsbibliothek der Johannes Gutenberg-Universität Mainz
- (wann)
-
2022
- Urheber
- DOI
-
10.25358/openscience-6937
- URN
-
urn:nbn:de:hebis:77-openscience-032d49ad-e188-44a4-848e-db0f65afd6bf3
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
25.03.2025, 13:54 MEZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Grus, Tilmann
- Universitätsbibliothek der Johannes Gutenberg-Universität Mainz
Entstanden
- 2022
Ähnliche Objekte (12)
Inhibitors of the prostate-specific membrane antigen (PSMA) for PET imaging and endoradiotherapy of prostate cancer
PSMA-targeting radiopharmaceuticals for prostate cancer Therapy: recent developments and future perspectives
Imaging and photodynamic therapy of prostate cancer using a theranostic PSMA-targeting ligand
DNA damage in blood leucocytes of prostate cancer patients during therapy with 177Lu-PSMA
Combination therapies to enhance the efficacy of PSMA-targeted radioligand therapy in prostate cancer
Development of PSMA inhibitors for molecular imaging and radio-guided surgery of prostate cancer
Development of inhibitors of the prostate specific membrane antigen (PSMA) for imaging and endoradiotherapy
Towards improving the efficacy of PSMA-targeting radionuclide therapy for late-stage prostate cancer - combination strategies
Hematologic safety of 177Lu-PSMA-617 radioligand therapy in patients with metastatic castration-resistant prostate cancer
Diagnostic value of additional 68Ga-PSMA-PET before 223Ra-dichloride therapy in patients with metastatic prostate carcinoma
Hematotoxicity and nephrotoxicity in prostate cancer patients undergoing radioligand therapy with [\(^177}\)Lu]Lu-PSMA I&T
⁶⁸Ga-PSMA PET for the assessment of metastatic prostate cancer
Inhibitors of the prostate-specific membrane antigen (PSMA) for PET imaging and endoradiotherapy of prostate cancer
PSMA-targeting radiopharmaceuticals for prostate cancer Therapy: recent developments and future perspectives
Imaging and photodynamic therapy of prostate cancer using a theranostic PSMA-targeting ligand
DNA damage in blood leucocytes of prostate cancer patients during therapy with 177Lu-PSMA
Combination therapies to enhance the efficacy of PSMA-targeted radioligand therapy in prostate cancer
Development of PSMA inhibitors for molecular imaging and radio-guided surgery of prostate cancer
Development of inhibitors of the prostate specific membrane antigen (PSMA) for imaging and endoradiotherapy
Towards improving the efficacy of PSMA-targeting radionuclide therapy for late-stage prostate cancer - combination strategies
Hematologic safety of 177Lu-PSMA-617 radioligand therapy in patients with metastatic castration-resistant prostate cancer
Diagnostic value of additional 68Ga-PSMA-PET before 223Ra-dichloride therapy in patients with metastatic prostate carcinoma
Hematotoxicity and nephrotoxicity in prostate cancer patients undergoing radioligand therapy with [\(^177}\)Lu]Lu-PSMA I&T
⁶⁸Ga-PSMA PET for the assessment of metastatic prostate cancer
Inhibitors of the prostate-specific membrane antigen (PSMA) for PET imaging and endoradiotherapy of prostate cancer
PSMA-targeting radiopharmaceuticals for prostate cancer Therapy: recent developments and future perspectives
Imaging and photodynamic therapy of prostate cancer using a theranostic PSMA-targeting ligand
DNA damage in blood leucocytes of prostate cancer patients during therapy with 177Lu-PSMA
Combination therapies to enhance the efficacy of PSMA-targeted radioligand therapy in prostate cancer
Development of PSMA inhibitors for molecular imaging and radio-guided surgery of prostate cancer
Development of inhibitors of the prostate specific membrane antigen (PSMA) for imaging and endoradiotherapy
Towards improving the efficacy of PSMA-targeting radionuclide therapy for late-stage prostate cancer - combination strategies
Hematologic safety of 177Lu-PSMA-617 radioligand therapy in patients with metastatic castration-resistant prostate cancer
Diagnostic value of additional 68Ga-PSMA-PET before 223Ra-dichloride therapy in patients with metastatic prostate carcinoma
Hematotoxicity and nephrotoxicity in prostate cancer patients undergoing radioligand therapy with [\(^177}\)Lu]Lu-PSMA I&T